Novo Nordisk A/S (NOVO-B.CO)
Copenhagen - Copenhagen Real Time Price. Currency in DKK
Add to watchlist
At close: 04:59PM CEST
| Previous Close | 979.70 |
| Open | 984.70 |
| Bid | 991.00 x 0 |
| Ask | 991.00 x 0 |
| Day's Range | 977.00 - 996.90 |
| 52 Week Range | 504.40 - 997.40 |
| Volume | |
| Avg. Volume | 2,503,166 |
| Market Cap | 4.383T |
| Beta (5Y Monthly) | 0.17 |
| PE Ratio (TTM) | 49.75 |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | 12.80 (1.29%) |
| Ex-Dividend Date | Mar 22, 2024 |
| 1y Target Est | N/A |
- Yahoo Finance
Eli Lilly unveils new manufacturing plant for GLP-1 pens
Eli Lilly unveiled its newest manufacturing facility in Concord, N.C., Friday. The facility will help alleviate GLP-1 shortages.
- Zacks
Novo Nordisk (NVO) Advances While Market Declines: Some Information for Investors
Novo Nordisk (NVO) closed the most recent trading day at $142.50, moving +0.01% from the previous trading session.
- Reuters
Novo Nordisk CEO to testify in US Senate hearing on high cost of Ozempic, Wegovy
A U.S. Senate health panel vote that was scheduled for its June 18 meeting, to decide whether to subpoena Novo to answer questions about U.S. prices for the blockbuster drugs, is no longer necessary and will be canceled, Senator Bernie Sanders, who chairs the committee, said. The subpoena would have required Novo President Doug Langa to testify at a July 10 hearing. Jorgensen will testify before the committee, and the hearing will be held in early September.
© 2024 Yahoo. All rights reserved.